Expert Interview
Discussing the Final Results from CORE-001 Phase 2 Trial of Cretostimogene Combined with Pembrolizumab for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer presented at 2024 ASCO Annual Meeting
Ticker(s): CGONUrology Specialists of Michigan
- Urology Specialist at Urology Specialists of Michigan
- Currently manages 200+ patients with Non-Muscle Invasive Bladder Cancer
- Will review ASCO results from CORE-001 Phase 2 Trial
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
